Obinutuzumab is a targeted treatment used primarily to treat chronic lymphocytic leukemia (CLL) and some non-Hodgkin lymphomas. It is a monoclonal antibody that binds to the CD20 protein found on the surface of B lymphocytes. Obinutuzumab binds to CD20 and identifies these cells for destruction by the immune system, hence reducing cancer cell numbers. It is frequently used in conjunction with other medications, such as chlorambucil, to enhance therapeutic effects. When administered intravenously, side effects may include infusion-related reactions, infections, and changes in blood counts. Its use has improved the prognosis for people with certain forms of cancer.